|
|
|
|
| LEADER |
01824nam a2200361 u 4500 |
| 001 |
EB002000825 |
| 003 |
EBX01000000000000001163726 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 130 |
0 |
|
|a AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) (October 2017)
|
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.)
|h Elektronische Ressource
|b indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults
|
| 246 |
3 |
1 |
|a AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.)
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, October 2017
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Muscle Spasticity / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Upper Extremity / physiopathology
|
| 653 |
|
|
|a Insurance, Health, Reimbursement / economics
|
| 653 |
|
|
|a Drug Costs
|
| 653 |
|
|
|a Botulinum Toxins, Type A / therapeutic use
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK534677
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults
|